{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:05:18Z","timestamp":1792098318690,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.ygyno.2007.12.024","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T14:51:46Z","timestamp":1205247106000},"page":"226-233","source":"Crossref","is-referenced-by-count":22,"title":["Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion"],"prefix":"10.1016","volume":"109","author":[{"given":"Saubhik","family":"Sengupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad M.","family":"Michener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Belinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Ganapathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2007.12.024_bib1","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/jnci\/dji289","article-title":"Annual report to the nation on the status of cancer, 1975\u20132002, featuring population-based trends in cancer treatment","volume":"97","author":"Edwards","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2007.12.024_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","article-title":"Cancer statistics, 2005","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2007.12.024_bib3","first-page":"g8","article-title":"Ovarian cancer: natural history and metastatic pattern","volume":"2","author":"Amadori","year":"1997","journal-title":"Front Biosci"},{"key":"10.1016\/j.ygyno.2007.12.024_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2007.12.024_bib5","first-page":"1223","article-title":"Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients","volume":"1","author":"Xu","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2007.12.024_bib6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jama.280.8.719","article-title":"Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers","volume":"280","author":"Xu","year":"1998","journal-title":"Jama"},{"key":"10.1016\/j.ygyno.2007.12.024_bib7","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1055-9965.1185.13.7","article-title":"Lysophospholipids are potential biomarkers of ovarian cancer","volume":"13","author":"Sutphen","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2007.12.024_bib8","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/0008-5472.CAN-05-1292","article-title":"Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells","volume":"66","author":"Ren","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2007.12.024_bib9","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1096\/fj.02-1145fje","article-title":"A novel laminin-induced LPA autocrine loop in the migration of ovarian cancer cells","volume":"17","author":"Sengupta","year":"2003","journal-title":"Faseb J"},{"key":"10.1016\/j.ygyno.2007.12.024_bib10","first-page":"3194","article-title":"Lysophosphatidic acid promotes matrixmetalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells","volume":"61","author":"Fishman","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2007.12.024_bib11","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1124\/mol.58.6.1188","article-title":"Lysophosphatidic acid receptors","volume":"58","author":"Contos","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ygyno.2007.12.024_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0090-6980(01)00105-8","article-title":"The LPA receptors","volume":"64","author":"Fukushima","year":"2001","journal-title":"Prostaglandins"},{"key":"10.1016\/j.ygyno.2007.12.024_bib13","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1038\/sj.onc.1210093","article-title":"Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion","volume":"26","author":"Sengupta","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2007.12.024_bib14","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1124\/mol.62.3.660","article-title":"Akt activation induced by lysophosphatidic acid and sphingosine-1-phosphate requires both mitogen-activated protein kinase kinase and p38 mitogen activated protein kinase and is cell-line specific","volume":"62","author":"Baudhuin","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ygyno.2007.12.024_bib15","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1242\/jcs.00679","article-title":"Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK","volume":"116","author":"Stahle","year":"2003","journal-title":"J Cell Sci"},{"key":"10.1016\/j.ygyno.2007.12.024_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1388-1981(02)00179-8","article-title":"Lysophosphatidic acid is a bioactive mediator in ovarian cancer","volume":"1582","author":"Fang","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ygyno.2007.12.024_bib17","doi-asserted-by":"crossref","first-page":"7983","DOI":"10.1158\/0008-5472.CAN-05-4381","article-title":"Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo","volume":"66","author":"Kim","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2007.12.024_bib18","doi-asserted-by":"crossref","first-page":"10564","DOI":"10.1074\/jbc.M412152200","article-title":"Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ygyno.2007.12.024_bib19","first-page":"880","article-title":"In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002)","volume":"6","author":"Hu","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2007.12.024_bib20","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1158\/1078-0432.CCR-05-2516","article-title":"Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling","volume":"12","author":"Davidson","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2007.12.024_bib21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1074\/mcp.T500003-MCP200","article-title":"Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma","volume":"4","author":"Sheehan","year":"2005","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.ygyno.2007.12.024_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1006\/bbrc.2000.4126","article-title":"Molecular cloning of a novel human gene on chromosome 4p11 by immunoscreening of an ovarian carcinoma cDNA library","volume":"280","author":"Luo","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ygyno.2007.12.024_bib23","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/dvdy.10332","article-title":"Embryonic stem cell and tissue-specific expression of a novel conserved gene, asrij","volume":"227","author":"Mukhopadhyay","year":"2003","journal-title":"Dev Dyn"},{"key":"10.1016\/j.ygyno.2007.12.024_bib24","doi-asserted-by":"crossref","first-page":"18952","DOI":"10.1016\/S0021-9258(17)30608-7","article-title":"A novel guanine nucleotide-binding protein coupled to the alpha 1-adrenergic receptor. II. Purification, characterization, and reconstitution","volume":"265","author":"Im","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ygyno.2007.12.024_bib25","first-page":"850","article-title":"Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines","volume":"57","author":"Johnson","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2007.12.024_bib26","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1158\/0008-5472.CAN-04-3931","article-title":"Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer","volume":"65","author":"Bapat","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2007.12.024_bib27","first-page":"735","article-title":"Paclitaxel inhibits natural killer cell binding to target cells by downregulating adhesion molecule expression","volume":"25","author":"Loubani","year":"2005","journal-title":"Anticancer Res"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825807010451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825807010451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:04:54Z","timestamp":1684281894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825807010451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0090825807010451"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2007.12.024","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}